All News

The impending repeal of Obamacare has sparked concerns that vulnerable groups will lose insurance coverage and access to treatment, including HIV/AIDS patients.

The addition of new a chief medical officer and a new chief commercial officer comes as the digital health provider is poised to scale up delivery of the National Diabetes Prevention Program in Medicare.

What we're reading, January 9, 2017: how Meals on Wheels is becoming the "eyes and ears" of the healthcare system; unease brewing among Republicans about repealing Obamacare without a replacement; and a doctor at the Cleveland Clinic faces disciplinary actions after publishing anti-vaccine rhetoric.

Delayed adjuvant chemotherapy, started up to 4 months following resection of non—small cell lung cancer (NSCLC) could still be beneficial to patients, according to a new study published in JAMA Oncology.

During an interview with Vox that was simulcast by the White House, President Barack Obama reviews where his signature law is working, where it isn't, and why Americans should demand to see what a replacement would look like.

These guidelines provide an overview of the current recommendations surrounding HIV/AIDS diagnosis, treatment, and complications.

As the prevalence of chronic obstructive pulmonary disease increases, self-management will become increasingly important. However, a new study has highlighted the difficulties of embedding self-management into routine care.

Payments for catastrophic coverage under Medicare Part D have more than tripled since 2010, rising past $33 billion in 2015, according to a new report from the Office of Inspector General (OIG). The report identified high-priced specialty drugs as a major driver of the increase in spending.

As the team at CMS prepares to hand the reins over to the next administration, Andy Slavitt, acting administrator of CMS, took the time to speak with Mandi Bishop, MA, CEO of Aloha Health, in the latest podcast of Managed Care Cast about what he learned in his role and what the next administration should keep in mind.

CDC has opened up a portal for public comments on its National Tobacco Prevention and Control Public Education Campaign to gather input on the effectiveness of its existing efforts on data collection.

The judge's ruling allows 30 days for an appeal but encourages the parties to work out a settlement. The case involves competing, expensive drugs to control cholesterol.

This week in managed care, readers chose the top healthcare news story of 2016, 4 physician groups appealed to Congress to have a replacement for Obamacare ready if it is repealed, and the American College of Physicians released a new guideline on oral medications for type 2 diabetes.

What we're reading, January 6, 2017: some Democrats are appealing to the GOP to consider bipartisan efforts to overhaul Obamacare instead of repealing it; enrollment for Affordable Care Act plans is up 2.3% over last year; and Democrats demand an ethics probe into Tom Price's stock trades.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

There are signs that some Republicans are uncomfortable with repealing President Barack Obama's signature law without taking steps to keep those who gained coverage from becoming uninsured.

In a letter to CMS, the National Association of Medicaid Directors contended that a 15-day limit on inpatient psychiatric treatment reimbursement is too short for effective treatment of some patients diagnosed with severe mental illness or substance use disorder.

The Health Resources and Services Administration (HRSA) within HHS has finalized a rule for all drug manufacturers who are required to make their drugs available to covered care providers under the 340B drug pricing program.

The intervention involves limiting carbohydrates to 40% of calories and having participants maintain muscle mass, so energy levels remain high.

As we approach the January 20 inauguration of Donald J. Trump as the 45th president of the United States, we come to the end of an all-too-brief era of unparalleled government transparency and leadership accessibility: Acting Administrator of CMS Andy Slavitt will be stepping down from his post.

While rapid innovations in the field of oncology have improved treatments, the magnitude and dimension of clinical benefits vary widely.

What we’re reading, January 5, 2017: Vice President Joe Biden will create a nonprofit organization to focus on cancer research and drug prices; school telemedicine could help kids stay in the classroom and out of the doctor’s office; bundled payments for joint replacements saved $5577 in spending per episode.

Contrary to popular opinion, hospitals that receive lower reimbursements from public programs often cut fees to private payers to adjust to the new normal. Medicaid expansion, in particular, has had a net positive effect because hospitals are faced with less uncompensated care.

Researchers in Australia conducted a systematic analysis of several randomized control trials that evaluated weight loss as an intervention for breast, endometrial, and ovarian cancer.

More hospitals are switching to employment-based affiliations with physicians, but a recent analysis found no association between conversion to an employment model and changes in mortality, readmissions, length of stay, or patient satisfaction rates.

A new single-patient case study, published in the New England Journal of Medicine, has raised the possibility of using CAR-T cells in the treatment of glioblastoma, an aggressive form of brain tumor.

An increasing prevalence of type 2 diabetes and poor glycemic control among youth in the United States has highlighted the need for early detection of prediabetes.

A survey of young adults revealed that those with arthritis reported significantly higher rates of employment and lower rates of education participation than their peers without arthritis.

What we're reading, January 4, 2017: Republicans in Congress may also make changes to Medicare; churches and faith-based organizations launch syringe exchanges; and judge rules Amgen's PCSK9 patent is valid.

The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.

A look at value-based insurance design, and how it provides a way to reduce financial barriers to care for people with chronic conditions.